Latest News-EVEREST MEDICINES Mediaroom_Page

Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases

GUANGZHOU, China, March 23, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the...

2023-03-23 17:52 2318

Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023

SHANGHAI, March 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical comp...

2023-03-15 20:45 2288

Everest Medicines Announces Partner Calliditas Therapeutics Reports Positive Topline Results from Phase 3 NefIgArd Trial Evaluating Nefecon in IgA Nephropathy

SHANGHAI, March 14, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2023-03-14 07:30 2543

Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company

SHANGHAI, March 13, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical comp...

2023-03-13 07:51 3113

Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"...

2023-02-28 07:30 5268

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy

SHANGHAI, Feb. 10, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical compa...

2023-02-10 07:30 5096

Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China

Study findings suggest that EVER206 is well-tolerated with no new safety signals, supporting next-p...

2023-01-18 07:30 3300

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company

--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities ...

2023-01-03 16:00 3651

Everest Medicines to Hold New Corporate Strategy Online Conference Calls

SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX: 1952), a biopharmaceutical company...

2022-12-30 08:05 4502

Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

--Further regulatory support for accelerated approval of Nefecon following NMPA's NDA acceptance wi...

2022-12-30 08:00 4871

Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma

--Everest owns complete pharmaceutical and vaccine value chain from discovery, clinical development...

2022-12-28 08:00 3296

Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis

SHANGHAI, Dec. 22, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its l...

2022-12-22 08:00 4135

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highli...

2022-12-15 08:00 6277

Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy

-- Taiwan Food and Drug Administration grants Accelerated Approval Designation (AAD) to Nefecon -- ...

2022-11-28 08:27 3610

Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy

-- NDA acceptance takes Everest closer to making this first-in-disease treatment available for prim...

2022-11-15 08:00 3568

Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults

-- Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®-- -...

2022-10-19 20:15 2546

Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections

SHANGHAI, Oct. 8, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest Medicines"...

2022-10-08 08:00 2757

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases

Advancement highlights Everest's potential in providing first-in-class therapies to global patients...

2022-09-26 08:00 3010

Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth

SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines (HKE...

2022-09-19 08:00 4797

Everest Medicines Announces the Departure of CEO, Kerry Blanchard

SHANGHAI, Aug. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX...

2022-08-26 07:30 3963